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The Epstein-Barr virus encoded 
LMP1 oncoprotein modulates cell 
adhesion via regulation of activin  
A/TGFβ and β1 integrin signalling
Mhairi A. Morris1, Christopher W. Dawson2, Louise Laverick3, Alexandra M. Davis1, 
Joe P. R. Dudman1, Sathuwarman Raveenthiraraj1, Zeeshan Ahmad1, Lee-Fah Yap4 & 
Lawrence S. Young5
Approximately 20% of global cancer incidence is causally linked to an infectious agent. Epstein-
Barr virus (EBV) accounts for around 1% of all virus-associated cancers and is associated with 
nasopharyngeal carcinoma (NPC). Latent membrane protein 1 (LMP1), the major oncoprotein encoded 
by EBV, behaves as a constitutively active tumour necrosis factor (TNF) receptor activating a variety 
of signalling pathways, including the three classic MAPKs (ERK-MAPK, p38 MAPK and JNK/SAPK). 
The present study identifies novel signalling properties for this integral membrane protein via the 
induction and secretion of activin A and TGFβ1, which are both required for LMP1’s ability to induce the 
expression of the extracellular matrix protein, fibronectin. However, it is evident that LMP1 is unable 
to activate the classic Smad-dependent TGFβ signalling pathway, but rather elicits its effects through 
the non-Smad arm of TGFβ signalling. In addition, there is a requirement for JNK/SAPK signalling 
in LMP1-mediated fibronectin induction. LMP1 also induces the expression and activation of the 
major fibronectin receptor, α5β1 integrin, an effect that is accompanied by increased focal adhesion 
formation and turnover. Taken together, these findings support the putative role for LMP1 in the 
pathogenesis of NPC by contributing to the metastatic potential of epithelial cells.
EBV is a ubiquitous human gammaherpesvirus that infects approximately 95% of the population worldwide, 
persisting as a lifelong, largely asymptomatic infection. However, aberrant latent infection with EBV is linked 
to the pathogenesis of various lymphoid and epithelial malignancies, including endemic Burkitt’s lymphoma, 
Hodgkin’s lymphoma, NPC and a proportion of EBV-positive gastric carcinomas1. Unlike the differentiated form 
of NPC, the non-keratinising and undifferentiated forms of NPC are unique among squamous cell carcinomas 
of the head and neck due to their universal association with EBV infection2. NPC is endemic to areas of China 
and South-East Asia, with a peak incidence of 20–30 cases per 100,000 per annum, while intermediate incidences 
are observed in North Africa and the Mediterranean basin3. While the contribution of EBV infection to the 
pathogenesis of NPC is still unclear, a number of EBV latent genes with proven growth modulatory potential are 
expressed within tumour cells. Here, EBV latent gene expression is restricted to EBV-nuclear antigen 1 (EBNA1), 
the non-coding EBER1 and EBER2 RNAs, the BART family of microRNAs, and variable expression of the latent 
membrane proteins, LMP1, LMP2A and LMP2B4. Although limited, analysis of rare premalignant lesions of the 
nasopharynx from patients in high-risk NPC regions has revealed the presence of monoclonal EBV genomes 
and detectable levels of LMP1 expression, suggesting a role for this viral oncogene in the early stages of NPC 
pathogenesis5.
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LMP1 is a 66 kDa integral membrane protein that shares signalling properties with members of the TNF 
receptor superfamily. LMP1 has been shown to engage the three classic mitogen-activated protein kinases 
(MAPKs): ERK-MAPK, p38 MAPK and JNK/SAPK, the canonical and non-canonical NF-κ B pathways, and 
the PI3K pathway6. LMP1 behaves as a classical oncogene, transforming rodent fibroblasts in vitro and rendering 
them tumourigenic in vivo4,7. In epithelial cells, LMP1 exerts similar growth-enhancing effects, promoting cell 
growth, stimulating migration and invasion, and modulating squamous epithelial differentiation8,9. Moreover, 
LMP1 is known to induce the expression of matrix metalloproteinases in vitro, which are secreted by tumour 
cells to breakdown the surrounding tissue stroma thereby enhancing tumour cell invasive potential10,11. In 
Madin-Darby Canine Kidney (MDCK) epithelial cells, LMP1 can profoundly alter their morphology, inducing 
a phenomenon known as epithelial-to-mesenchymal transition (EMT)12, a phenomenon that may be linked to 
the ability of LMP1 to induce cancer stem/progenitor cell-like properties in certain epithelial cell lines13. When 
targeted to the epidermis of transgenic mice, LMP1 was found to induce a form of epidermal hyperplasia, sim-
ilar to that observed in psoriasis14,15, findings which are supported by the observation that LMP1 induces an 
inflammatory keratinocyte wounding response in epithelial cells in vitro10. LMP1 is also known to induce various 
proteins with pro-angiogenic functions, such as MMP1 and VEGF16,17, and VEGF-C has been shown to induce 
lymphangiogenesis in NPC; however, the authors do not see a correlation between LMP1 expression and VEGF-C 
expression18. Collectively, these findings support a role for LMP1 in the pathogenesis of NPC by modulating the 
cellular phenotype.
The TGFβ superfamily comprises a range of pleiotropic growth factors produced by a diverse range of cell 
types that modulate cell migration, cell adhesion, proliferation, differentiation and survival19. TGFβ 1 is the pro-
totypic member but others include TGFβ 2 and TGFβ 3, and the activins. Activin A and TGFβ primarily signal 
through very similar pathways involving the regulatory signalling molecules called Smads. Depending on the 
different transcription factors they interact with, Smads can either stimulate or repress the transcription of their 
target genes19,20. Alternative, Smad-independent signalling pathways also exist for both activin A and TGFβ . 
For instance, activin A can signal through the RhoA-ROCK-MEKK1-JNK and MEKK1-p38 signalling cascades, 
which are implicated in the actin cytoskeleton remodelling and cell migration involved in epithelial morphogen-
esis21; whilst the small GTPase, Ras, and the MAPKs, ERK, p38 and JNK, are all important downstream factors in 
Smad-independent TGFβ signalling22.
Both activin A and TGFβ are implicated in the processes of wound healing and tumourigenesis23,24. Indeed, 
the expression of various activin family members has been detected in a number of cancers, for example, prostate 
cancer25, breast cancer26, and retinoblastoma27. Both molecules have been shown to stimulate the expression and 
secretion of ECM proteins such as fibronectin and type I collagen23,28. The integrins are a family of cell surface 
receptors that bind to various ECM proteins: in cell culture, or in response to wounding, fibronectin specifically 
binds α 5β 129.
In the current study, the induction of activin A and TGFβ by LMP1 was investigated further, with particular 
emphasis on their role in generating a fibrotic response. Microarray analysis of tetracycline-inducible SCC12F 
cells expressing LMP1 identified TGFβ and activin A as LMP1 target genes in keratinocytes10. However, LMP1 
has previously been shown to inhibit the activation of TGFβ /Smad signalling in epithelial cells and fibroblasts, 
via an NF-κ B-dependent mechanism30,31. The apparent contradiction between these studies supports the require-
ment for further investigation into the effects of LMP1-induced activin A and/or TGFβ on epithelial cells in vitro.
The present study demonstrates that LMP1-mediated induction of activin A and/or TGFβ are required to 
induce the expression and secretion of fibronectin, a phenotype associated with the fibrotic response in wounded 
keratinocytes in preparation for migration and invasion, and a precursor to neoplasia. However, contrary to 
expectations, the findings presented here demonstrate that Smad-dependent transcription is inhibited in 
LMP1-expressing cells, and furthermore confirm the Smad-independency of fibronectin induction by LMP1. 
Furthermore, this study demonstrates that LMP1-mediated fibronectin induction is abrogated by inhibiting JNK/
SAPK signalling, corroborating previous findings. In addition, an increase in the activation of β 1 integrins and 
the expression of α 5 integrins on the surface of LMP1-expressing cells is observed. Since α 5β 1 integrin is the 
major fibronectin receptor, these findings therefore support the hypothesis that LMP1 may be upregulating the 
expression and secretion of fibronectin and cell surface expression of its receptor in order to facilitate invasion 
and metastasis. Finally, the findings highlight a role for activin A and/or TGFβ signalling in LMP1-enhanced 
cell adhesion and spreading. Taken together, these data support a role for LMP1 in mediating an invasive and 
metastatic phenotype in epithelial cells in vitro, thereby suggesting a putative role for LMP1 in the pathogenesis 
of NPC in vivo. This may have wider implications for the identification of therapeutic targets for NPC and other 
EBV-associated cancers, which bear many common features.
Results
LMP1 increases the expression and secretion of activin A and TGFβ and enhances fibronectin 
synthesis, secretion and expression. Building on previous observations outlining the ability of LMP1 
to induce the expression of activin A and TGFβ in a tet-LMP1 inducible system10, the expression and secretion 
of activin A and TGFβ was investigated in SCC12F epithelial cells stably expressing LMP1. Immunoblotting con-
firmed the upregulation of activin A at the protein level in LMP1-expressing SCC12F cells (Fig. 1a). Furthermore, 
ELISA confirmed a 2.61-fold increase in TGFβ 1 levels and a 1.37-fold increase in activin A levels secreted in 
conditioned medium taken from LMP1-expressing cells (Fig. 1b,c; with p-values < 0.01 and < 0.001, denoted 
by two and three asterisks, respectively). These results are in agreement with previously published data that the 
levels of activin A and TGFβ 1 were up-regulated in micro-dissected primary NPC cells compared with normal 
epithelium32.
As shown in Fig. 1d, Western blotting confirmed that LMP1-expressing SCC12F cells expressed signifi-
cantly higher levels of cellular fibronectin compared to control cells. Furthermore, 35S-Methionine labelling and 
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immunoprecipitation confirmed increased translation of fibronectin in LMP1-expressing cells (Fig. 1e), while 
ELISA (Fig. 1f) confirmed that LMP1-expressing cells synthesised and secreted higher levels of fibronectin 
compared to control cells. Interestingly, immunofluorescence staining of cells cultured in situ confirmed that 
LMP1-expressing cells deposited higher amounts of fibronectin into their extracellular matrix than control cells 
(Fig. 1g) suggesting that LMP1 modulates ECM protein incorporation into cell-associated matrix. Given that 
TGFβ and activin A are known to participate in fibrotic responses under conditions of chronic inflammation, and 
that LMP1 can upregulate the expression of activin A and TGFβ , it is logical to hypothesise that LMP1-mediated 
fibronectin induction may be elicited by activin A and/or TGFβ .
LMP1-mediated fibronectin induction is dependent on activin A and/or TGFβ. Both activin A and 
TGFβ are known to stimulate the expression and secretion of ECM proteins, including fibronectin23,33. Moreover, 
both cytokines have been linked to fibrosis of the liver, lungs and kidneys34,35. According to a study published in 
2002 by Laping and colleagues, the TGFβ -mediated induction of fibronectin mRNA expression is not significant 
Figure 1. Analysis of expression of activin A (a) and secretion of TGFβ 1 (b) and activin A (c) in LMP1-
expressing SCC12F cells compared with control cells. The student’s t-test confirmed the statistical significance 
of the difference in cytokine secretion relative to the control, with p values of < 0.01 and < 0.001, denoted by 
two and three asterisks, respectively. LMP1 expression in SCC12F cells is associated with increased fibronectin 
synthesis, secretion and deposition into cell-associated matrix, as measured by (d) Western blotting,  
(e) 35S Methionine labelling and immunoprecipitation, (f) ELISA, and (g) immunofluorescence staining.
www.nature.com/scientificreports/
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until 16 hours post treatment; thus, this time-point was used in the current study36. Furthermore, TGFβ -mediated 
fibronectin induction has been shown to be independent of Smad4 and instead requires a signal from JNK/SAPK, 
but not ERK-MAPK or p38 MAPK, in human fibrosarcoma cell lines33. In order to assess the contribution of 
LMP1-induced activin A and/or TGFβ to the induction of fibronectin expression, control and LMP1-expressing 
cells were treated with the small molecule inhibitor of the activin A and TGFβ type I receptor, SB43154237.
Figure 2 demonstrates the requirement for signalling through activin A and/or TGFβ 1 for the induction of 
fibronectin in LMP1-expressing cells at the mRNA level (Fig. 2a). Moreover, the addition of exogenous activin 
A and TGFβ 1 augments LMP1’s ability to induce fibronectin expression at the protein level (Fig. 2b). A role for 
activin A or TGFβ in this response was confirmed, as fibronectin expression was abrogated by addition of the 
activin A/TGFβ inhibitor, SB431542.
LMP1 inhibits Smad-dependent transcription and LMP1-mediated fibronectin induction 
occurs via a Smad-independent mechanism. It has previously been reported that LMP1 inhibits 
TGFβ -mediated growth arrest and the activation of Smad-dependent signalling in epithelial cells and fibroblasts 
via an NF-κ B-dependent mechanism30,31; however, as yet there is no published data concerning the phosphoryl-
ation status of the downstream signalling intermediates, the Smads, in response to LMP1 expression. Indeed, in 
agreement with published observations, data presented here shows that LMP1 failed to activate Smad-dependent 
transcription in SCC12F cells, as assessed by dual luciferase reporter assays using either a Smad2/3-dependent 
activin response element (ARE-Luc) which binds Smad2 and Smad338 or the Smad3/4-binding sequences, termed 
CAGA boxes (CAGA-Luc) which binds Smad3 and Smad439 (Fig. 3a). It is interesting to note, however, that 
despite this apparent inhibition of Smad-dependent transcription, LMP1 expression still enhanced basal Smad2 
phosphorylation – a general measure of activin A and TGFβ activity (Fig. 2b).
As a consequence of this observation, the requirement for Smad activity in LMP1-mediated fibronectin induc-
tion was also assessed. Indeed, fibronectin induction has been reported to be a Smad4-independent TGFβ target 
gene33. Since Smad4 expression is absolutely required to transduce Smad-dependent signalling from both activin 
and TGFβ receptors40, the Smad-independency of LMP1-mediated induction of fibronectin was investigated 
using HaCaT cells stably expressing a tetracycline-regulatable Smad4 siRNA (Fig. 3b). The cells were then tran-
siently transfected with low levels of LMP1 to be more representative of NPC, following which the ability of LMP1 
to enhance fibronectin secretion in the presence and absence of Smad4 was assessed. As demonstrated in Fig. 3c, 
LMP1’s ability to enhance fibronectin secretion did not appear to be affected by Smad4 silencing upon addition 
of doxycycline.
LMP1-mediated fibronectin induction is promoted via the JNK/SAPK pathway. Since 
LMP1-mediated fibronectin induction requires a signal from activin A and/or TGFβ , yet Smad-dependent tran-
scription is inhibited by LMP1, the relative contribution of various Smad-independent pathways on this cellular 
phenotype was subsequently investigated. In addition to the canonical Smad-dependent pathway, both activin 
A and TGFβ have been shown to signal via Smad-independent, yet receptor-dependent, pathways including 
Figure 2. Treatment of control and LMP1-expressing SCC12F cells with the activin A/TGFβ receptor (ALK5) 
inhibitor, SB431542, reduces fibronectin transcription as measured by qPCR (a); and reduces fibronectin 
protein expression (b). Western blotting confirmed abrogation of Smad2 phosphorylation by addition of 
SB431542 with no effect on total Smad2 levels.
www.nature.com/scientificreports/
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the three MAPK pathways, JNK/SAPK, ERK-MAPK and p38 MAPK, and also through the PI3K/Akt signalling 
pathway41.
Using a panel of small molecule inhibitors, the common signalling pathways engaged by LMP1 that may be 
responsible for LMP1-mediated fibronectin induction were interrogated. The results revealed a role for JNK/
SAPK signalling in LMP1’s ability to induce fibronectin expression (Fig. 4a). Moreover, it is evident that inhibi-
tion of activin A and/or TGFβ does not affect LMP1’s ability to activate JNK/SAPK signalling (Fig. 4b).
LMP1 activates and upregulates the cell surface expression of the fibronectin receptor, integrin 
α5β1. One of the possible downstream consequences of LMP1’s ability to induce fibronectin could be to acti-
vate the cognate receptors, leading to a host of other signalling events, for example to enhance cell survival and 
promote migration. Indeed, LMP1 expression results in an increase in the number of active β 1 integrins found 
on the surface of SCC12F cells, as assessed by flow cytometry using an antibody that recognises conformationally 
“active” β 1 integrins (Fig. 5a). Moreover, the cell surface levels of the α 5 integrin subunit were also elevated in 
response to LMP1 expression (Fig. 5a). The enhanced activation of β 1 integrins was confirmed by immunofluo-
rescence staining of cells grown in situ, which demonstrated an increased levels of conformationally “active” β 1 
integrins on the surface of LMP1-expressing cells, particularly at sites of focal adhesion (Fig. 5b; white arrows). 
This is supported by the finding that the expression of talin, an associated protein that is only recruited to sites of 
integrin activation42, is also enhanced in LMP1-expressing cells where it can be seen as punctate staining around 
the edge of the adherent cells, which are far larger than the control counterparts, indicative of enhanced adhesion 
(Fig. 5c). These data support the hypothesis that LMP1 may increase the synthesis and secretion of fibronectin, 
whilst also upregulating the cell surface expression of α 5β 1 integrins, to facilitate its own autocrine pro-survival 
and pro-metastatic signalling.
LMP1 promotes cell attachment and spreading and increases focal adhesion formation in 
response to adhesion to fibronectin. Formation and disassembly of focal adhesions, also known as 
focal adhesion turnover, is a dynamic process that occurs during cell migration and is mediated via integrin 
receptor engagement with ECM proteins. To confirm that LMP1 stimulates the expression and activity of β 1 
integrins, control and LMP1-expressing cells were serum starved overnight, recovered as single cell suspensions 
and plated onto fibronectin-coated slides. At various times, cells were fixed and stained for vinculin, a compo-
nent of focal adhesions. As shown in Fig. 6, LMP1-expressing cells adhered more rapidly to fibronectin than 
control cells, assembling robust focal adhesions, as marked by vinculin staining. At later time points (1hr–4hrs), 
Figure 3. Renilla luciferase reporter assays confirmed LMP1’s inability to activate Smad2/4-mediated gene 
transcription (ARE-Luc) and Smad3/4-mediated gene transcription (CAGA-Luc; (a). Effectiveness of Smad4 
siRNA upon addition of 5 g/ml doxycycline was confirmed by Western blotting (b). The ability of LMP1 to 
induce fibronectin secretion was confirmed by ELISA to be Smad-independent in HaCaT cell lines stably 
expressing tetracycline-inducible siRNA to Smad4 (c).
www.nature.com/scientificreports/
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LMP1-expressing cells attained higher levels of spreading. These findings confirmed that LMP1 stimulates integ-
rin activity, which facilitates cell attachment and spreading.
LMP1 activates ERK-MAPK at the leading edge of invadopodia in response to adhesion onto 
fibronectin. ERK-MAPK is known to be activated at points of focal adhesion turnover and serves as a marker 
for increased integrin-mediated adhesion43. Further to our previous observations that LMP1 can enhance the rate 
of cell motility in an ERK-dependent manner44, ERK-MAPK activation in response to LMP1-mediated adhesion 
to fibronectin was investigated. Figure 7a shows distinctly elevated levels of active, phosphorylated ERK-MAPK 
at the edge of the cell protrusions in LMP1-expressing cells (red arrows). Interestingly, the activated ERK-MAPK 
does not always co-localise with vinculin (white arrows) – a component of the focal adhesion complex – a 
phenomenon that is likely due to the timing of focal adhesion complex formation and turnover. Also, Fig. 7b 
demonstrates some degree of co-localisation between talin (white arrows) and phosphorylated ERK-MAPK (red 
arrows).
The increased rate of cell attachment and spreading onto fibronectin-coated slides observed 
with LMP1 expression can be abrogated by inhibiting activin A/TGFβ signalling. Further to these 
observations, data presented here demonstrates that inhibition of activin A/TGFβ signalling can abrogate LMP1’s 
ability to enhance cell adhesion and to spread on fibronectin-coated slides (Fig. 8). Cells were cultured in the 
presence and absence of the type I activin A/TGFβ receptor inhibitor, SB431542, overnight prior to recovery and 
seeding as single cell suspensions onto fibronectin-coated slides for various time-points. Immunofluorescence 
staining for vinculin and active ERK-MAPK revealed an enhanced rate of focal adhesion formation in untreated 
LMP1-expressing cells compared to their untreated control counterparts. However, the addition of SB431542 
retarded the rate of adhesion onto fibronectin in the LMP1-expressing cells, but not in their control counterparts 
(Fig. 8). These findings support the hypothesis that LMP1 is utilising activin A and/or TGFβ signalling to confer 
an invasive and migratory phenotype on epithelial cells by enhancing the rate of adhesion and spreading onto 
fibronectin, an ECM protein which is itself upregulated in response to activin A/TGFβ .
Figure 4. Western blotting confirmed the requirement for LMP1-mediated JNK/SAPK signalling in the 
induction of fibronectin using anisomycin, which stimulates JNK/SAPK signalling, and SP600125, a specific 
small molecule inhibitor of the JNK/SAPK pathway (a). The activation of JNK/SAPK signalling by LMP1 is not 
affected by addition of the activin A/TGFβ inhibitor, SB431542 (b).
www.nature.com/scientificreports/
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Discussion
NPC is a highly metastatic disease in which LMP1 is believed to play an important role in the early stages of dis-
ease pathogenesis4,6. Findings presented here identify a novel mechanism by which LMP1 alters cellular signalling 
and behaviour in vitro, pointing to a mechanism by which it could contribute to tumour progression and the focal 
adhesion complex formation and turnover that comprises the early stages of metastasis in NPC in vivo. The ability 
of LMP1 to stimulate fibronectin expression and secretion (Fig. 1), and to enhance cellular adhesion and migra-
tion on fibronectin (Figs 6 and 7) is suggestive of a role for LMP1 in the metastatic process in NPC.
Previous studies have highlighted a role for LMP1 in abrogating TGFβ -mediated growth inhibition and 
Smad-dependent transcription through a mechanism involving NF-κ B activation30,31. This current study demon-
strates that LMP1 can enhance the expression and secretion of both activin A and TGFβ to induce fibronectin 
expression and secretion (Fig. 2), and that although LMP1 promotes Smad2 protein phosphorylation (Fig. 2), it 
Figure 5. Flow cytometry reveals increased levels of active β1 integrins and integrin α5 on the surface 
of LMP1-expressing SCC12Fs when compared with controls. Calculation of the Mean Fluorescent 
Intensity (MFI) revealed a 1.45-fold increase in active integrin β 1, and a 1.61-fold increase in integrin α 5 (a). 
Immunofluorescence staining reveals elevated, punctate staining of active β 1 integrins (b) and talin (c) at sites 
of focal adhesion in LMP1-expressing cells.
www.nature.com/scientificreports/
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inhibits Smad-dependent transcription (Fig. 3); moreover, the ability of LMP1 to induce fibronectin expression 
and secretion is Smad-independent (Fig. 3). Findings presented here provide a novel mechanistic insight into 
LMP1’s ability to exploit the well-documented “double-edged sword” nature of TGFβ signalling, whereby it atten-
uates TGFβ -mediated cytostasis, yet utilises the pro-fibrotic nature of this superfamily of cytokines by engaging 
an alternative signalling pathway via JNK/SAPK, in line with other published observations33. It is important to 
note that LMP1-mediated engagement of the JNK/SAPK pathway is itself independent of activin A/TGFβ signal-
ling since inhibition using the type I receptor inhibitor, SB431542, failed to have any effect on intracellular levels 
of phosphorylated JNK (Fig. 4b).
Fibronectin is the major ligand for the α 5β 1 integrin receptor45 and is classically upregulated in response to 
keratinocyte wounding46. Increased levels of both α 5 and active β 1 integrins were observed on the cell surface of 
LMP1-expressing cells (Fig. 5a), along with the focal adhesion accessory protein, talin, which is only associated 
with activated integrins (Fig. 5b). These findings may suggest two things: 1) that LMP1 stimulates the production 
of a ligand to engage integrin signalling; and 2) that LMP1 increases the cell-surface expression of integrins to 
augment the outside-in signalling cascade activated by integrins. Further work is required to assess the extent of 
active integrin signalling in LMP1-expressing cells.
Previous observations have highlighted a role for ERK-MAPK signalling in LMP1’s ability to enhance cell 
motility and invasiveness44. Immunofluorescence staining for the focal adhesion protein, vinculin, highlights 
the increased rate of focal adhesion assembly and turnover in LMP1-expressing cells when compared with their 
control counterparts (Fig. 6). Moreover, an enhanced activation of ERK-MAPK, which is known to localise to 
points of focal adhesion43, is observed at points of focal adhesion in cells expressing LMP1 (Fig. 7). Allied to this, 
the requirement for activin A and/or TGFβ signalling in the adhesiveness of LMP1-expressing cells is highlighted, 
since treatment with the type I receptor inhibitor slows their rate of attachment and spreading onto fibronectin 
Figure 6. Immunofluorescence staining for vinculin revealed increased rates of attachment of LMP1-
expressing SCC12F cells to fibronectin and increased focal adhesion formation at the edge of spreading 
cells. 
www.nature.com/scientificreports/
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(Fig. 8). Since activin A and TGFβ are known to signal through the ERK-MAPK pathway, it would be convenient 
to hypothesise that this phenomenon merely represents an additional tier of signalling in this phenotypic effect of 
LMP1 expression. However, since inhibition of activin A and/or TGFβ fails to affect LMP1-mediated ERK acti-
vation (Fig. 8), these findings suggest that LMP1 can engage ERK-MAPK signalling without the requirement for 
a signal from activin A and/or TGFβ , and that it can utilise more than one signalling pathway to elicit its effects.
In summary, the findings presented here demonstrate that the EBV-encoded oncoprotein, LMP1, activates 
signalling through activin A and TGFβ 1 to induce the expression, secretion and deposition of the extracellular 
matrix protein, fibronectin. Moreover, these effects are mediated via a Smad-independent mechanism involving 
JNK/SAPK, but LMP1-mediated JNK/SAPK itself is not abrogated by addition of the small molecule inhibitor 
for the activin A and TGFβ receptor, ALK5. In addition, LMP1 upregulates the cell surface expression and acti-
vation of integrins, resulting in enhanced adhesion to fibronectin. These interlinked observations are summa-
rised in the schematic in Fig. 9. Taken together, these findings demonstrate the varied and far-reaching effects of 
LMP1-mediated activin A and TGFβ signalling in epithelial cells in vitro, pointing to a putative role for LMP1 in 
the metastatic potential of NPC cells in vivo. While further studies are required to examine this phenomenon in 
more detail, several studies have confirmed that EBV-positive NPC overexpress activin A and/or TGFβ 32,47. This, 
coupled with the findings of Ma and colleagues48, who found a direct correlation between the levels of LMP1 and 
the expression of fibronectin, suggests that induction of fibronectin by activin A/TGFβ may contribute to tumour 
cell invasiveness in vivo.
Figure 7. Immunofluorescence staining and confocal microscopy reveal increased levels of active ERK-MAPK 
(red arrows), at the edge of spreading cells, alongside vinculin (a) and talin (b; both white arrows) in LMP1-
expressing cells when plated onto fibronectin-coated slides.
www.nature.com/scientificreports/
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Since fibronectin induction is a characteristic feature of wounded keratinocytes in tissue fibrosis, and fibrosis 
is itself a known precursor to neoplastic lesions, future work will look to utilise these mechanistic insights into 
the signalling intermediates required for such a response in order to identify putative therapeutic targets. Not 
only will this be of benefit for the treatment of EBV-associated cancers such as NPC, it will have far-reaching 
implications for the treatment of many other virus- and infectious agent-associated cancers, which bear many 
common features.
Figure 8. The enhanced rate of adhesion and spreading onto fibronectin-coated slides observed in LMP1-
expressing SCC12Fs is abrogated by addition of the activin A/TGFβ small molecule inhibitor, SB431542, as 
visualised by immunofluorescence staining for active ERK-MAPK (red) and vinculin (green). 
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Materials and Methods
Cell lines and tissue culture. The human epithelial cell line SCC12F49 and a clone of SCC12F cells stably 
expressing LMP1 were cultured as described previously50. The HaCaT cell lines stably expressing the Tet repressor 
(TR) and the Tet-inducible Smad4 siRNA were a kind gift from Professor Caroline Hill, and were established as 
described previously40.
The recombinant human activin A protein (Peprotech, London, UK) was reconstituted in water to a concen-
tration of 50 μ g/ml, further diluted to a concentration of 10 μ g/ml in PBS containing 2 mg/ml albumin, and used 
at a final concentration of 10 ng/ml. Recombinant human TGFβ 1 (Peprotech) was reconstituted in 10 mM citric 
acid, pH 3.0, to a concentration of 50 μ g/ml, further diluted to a concentration of 10 μ g/ml in PBS containing 
2 mg/ml albumin, and used at a final concentration of 10 ng/ml. The activin/TGFβ type I receptor inhibitor, 
SB431542 (Tocris, Bristol, UK), was dissolved in DMSO to a concentration of 10 mM and used at a final concen-
tration of 10 μ M. JNK/SAPK signalling was stimulated using anisomycin (Sigma Aldrich, Dorset, UK), reconsti-
tuted in DMSO to a concentration of 25 mg/ml and used at a final concentration of 250 ng/ml. The small molecule 
JNK/SAPK inhibitor, SP600125 (Sigma), was dissolved in DMSO at a concentration of 10 mM and used at a final 
concentration of 10 μ M.
Western blot analysis. Standard immunoblotting procedures51 were used to detect LMP1 (with mouse 
CS1-4 at 1:5), activin A (with mouse anti-inhibin β A at 1:50 [Serotec, Oxfordshire, UK]), β -actin (with mouse 
anti-β -actin at 1:20,000 [Sigma]), fibronectin (with mouse anti-fibronectin at 1:100 [Sigma]), phosphorylated 
Smad2 Ser465/Ser467 (with rabbit anti-pSmad2 at 1:250 [Cell Signaling Technology, Hitchin, UK]), Smad2 (with 
rabbit anti-Smad2 at 1:250 [Cell Signaling Technology]), Smad4 (with rabbit anti-Smad4 at 1:250 [Cell Signaling 
Technology]), phosphorylated JNK/SAPK (with rabbit anti-pJNK/SAPK at 1:500 [Cell Signaling Technology]), 
JNK/SAPK (with rabbit anti-JNK/SAPK at 1:500 [Cell Signaling Technology]).
Quantitative PCR (qPCR). RNA was extracted using EZ-RNA total RNA isolation kit (Geneflow, Lichfield, 
UK) and amplification by qPCR was performed using and ABI 7500 real-time PCR machine following standard pro-
cedures. A TaqMan primer probe set for fibronectin was purchased from Applied Biosystems (Hs01549937_m1), 
together with GAPDH as a standard control.
ELISA. The presence of Activin A and TGFβ in the supernatants of cultured cells was determined by ELISA 
carried out following standard procedures, according to the manufacturers’ instructions (TGFβ – Promega, 
Southampton, UK; Activin A – R&D Systems, Abingdon, UK). Cells were cultured in serum-free medium sup-
plemented with 0.5% BSA for 16 h prior to collection of conditioned medium.
Transient transfections and luciferase reporter assays. Transient transfection was performed using 
the lipofectamine and plus reagent system according to manufacturer’s instructions (Life Technologies, Paisley, 
UK). The dual luciferase reporter assay (Promega) was carried out according to the manufacturer’s instructions, 
using the Renilla plasmid to control for transfection efficiency in addition to the following reporter constructs: 
pGL3 basic (Promega); ARE-Luc38; and CAGA-Luc39.
Immunofluorescence staining. Cells were cultured in medium containing 0.5% BSA for 16 h prior to 
recovery as single-cell suspensions and maintained in suspension for 60 min in the presence and absence of the 
activin A/TGFβ inhibitor, SB431542. Cells (104/100 μ l) were plated onto slides coated with fibronectin (10 μ g/
ml) and allowed to adhere for 60 min. Slides were fixed in 4% paraformaldehyde, then permeabilised in 0.5% 
Triton X-100 (Sigma) prior to staining simultaneously with antiserum specific for vinculin (Sigma), talin (Abcam, 
Cambridge, UK) and active ERK-MAPK (Promega), followed by Alexa Fluor 488-conjugated anti-mouse and 
Figure 9. Schematic diagram summarising the mechanisms by which LMP1 induces fibronectin expression 
and deposition, and the downstream consequences of this phenomenon. 
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534-conjugated anti-rabbit antibodies (Molecular Probes, Paisley, UK). Slides were mounted with DABCO and 
viewed using confocal laser microscopy.
Flow cytometry to detect levels of cell surface integrins. Cells were cultured in serum-free medium 
supplemented with 0.5% BSA for 16 h prior to harvesting in a weak trypsin:EDTA solution (1:20) to avoid cleav-
age of cell surface receptors. 2 × 105 cells per reaction were plated into a pre-chilled V-bottomed 96-well plate 
and centrifuged at 1500 × g for 3 min at 4 oC. Cell pellets were washed twice in ice cold 1% FCS/PBS, then resus-
pended in 1% FCS/PBS containing a 1:50 dilution of active β 1 integrin antibody and incubated on ice for 100 min 
in the dark. Cell pellets were washed three more times prior to resuspension in ice cold 1% FCS/PBS containing 
a 1:1000 dilution of the anti-mouse FITC-conjugated secondary antibody and incubated on ice for 1 hour in the 
dark. An anti-IgG antibody was included as an isotype control. Following three more washes, cell pellets were 
finally resuspended in 100 μ l of ice cold 1% PFA/PBS and transferred to labelled 5 ml polystyrene round bottom 
Falcon tubes (BD Biosciences, Oxford, UK) where a further 400 μ l of 1% PFA/PBS was added. Samples were read 
on a Coulter Epics XL-MCLTM flow cytometer.
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